Sign In
Buy SNY
$43.98
-0.680 (-1.52%)
At Close: Jul 20, 2026
ACAAI: Sanofi and Regeneron's Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review
Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey
Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey
UPDATE - Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey
08:47pm, Monday, 27'th Oct 2025
Expanded 10-plus-year collaboration will leverage Medidata Experiences with the goal of streamlining clinical processes and data, enhancing patient care Expanded 10-plus-year collaboration will levera
Sanofi: Is Dupixent Too Successful?
02:32pm, Friday, 24'th Oct 2025
Sanofi delivered strong Q3 results despite currency headwinds. The company's dependence on Dupixent is increasing. A broad immunology pipeline and the Blueprint Medicines acquisition should help addre
Sanofi Q3: Cash-Rich, Cheap, And Loading 2026 Shots On Goal
01:37pm, Friday, 24'th Oct 2025
Sanofi (SNY) remains a Buy, driven by Dupixent's robust growth and expanding indications, notably with the recent COPD launch. SNY's Q3 saw total revenues rise 7% CER to €12.43 billion, with Dupixen
Sanofi (SAN:CA) Q3 2025 Earnings Call Transcript
01:37pm, Friday, 24'th Oct 2025
Sanofi (SAN:CA) Q3 2025 Earnings Call Transcript
Sanofi Q3 Earnings Beat, Dupixent Drives Growth as Vaccines Decline
11:06am, Friday, 24'th Oct 2025
Sanofi's Q3 earnings top forecasts as Dupixent surges past EUR 4B in sales, offsetting weakness in vaccines.
Dupixent Pushes Sanofi's Quarterly Sales Past $14.5 Billion Mark
10:47am, Friday, 24'th Oct 2025
Sanofi SA (NASDAQ:SNY) reported third-quarter sales of $14.55 billion (12.43 billion euros), beating the consensus of $14.46 billion. Sales increased 2.3% year over year, up 7% in constant currency.
Sanofi Earnings Driven by New Medicine Sales, Dupixent Performance
02:55am, Friday, 24'th Oct 2025
Pharmaceutical launches and increased demand for its blockbuster Dupixent drug lifted net sales by 7% in the third quarter.
Sanofi's quarterly profit boosted by Dupixent and newer drugs, forecast unchanged
01:35am, Friday, 24'th Oct 2025
France's Sanofi reported a third-quarter profit that beat analysts' expectations on Friday, boosted by strong demand for its anti-inflammatory drug Dupixent and newer medicines.
Press release: Q3: continued sales and earnings progress
01:30am, Friday, 24'th Oct 2025
Q3: continued sales and earnings progress Paris, October 24, 2025 Q3 sales growth of 7.0% at CER1 and business earnings per share (EPS)2 of €2.91 Pharma launches increased sales by 57.1%, reaching �
Sanofi Deepens Partnership with Medidata to Expedite the Development of New Therapies with an Improved Patient Journey
01:00am, Thursday, 23'rd Oct 2025
Expanded 10-plus-year collaboration will leverage Medidata Experiences, enabling Sanofi to streamline operations, refine data quality, and enhance patient care Expanded 10-plus-year collaboration will
Sanofi Deepens Partnership with Medidata to Expedite the Development of New Therapies with an Improved Patient Journey
SNY's Efdoralprin Alfa Meets Key Endpoints in Rare Disease Study
11:20am, Wednesday, 22'nd Oct 2025
Sanofi's efdoralprin alfa meets all key endpoints in a global phase II study, showing potential as a first restorative recombinant therapy for AATD.
